Comparison of morphologic and immunohistochemical features of cervical microglandular hyperplasia with low-grade mucinous adenocarcinoma of the endometrium

International Journal of Gynecological Pathology

Volumn 22, Issue 3, 2003, Pages 261-265

  Qiu, Wansong ^a   Mittal, Khush ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

CEA; Cervical microglandular hyperplasia; Endometrial adenocarcinoma; MIB 1; Mucinous adenocarcinoma; Vimentin

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR; PROTEIN P53; VIMENTIN;

ADULT; AGED; ARTICLE; CELL NUCLEUS; CELL STRUCTURE; CELL VACUOLE; CONTROLLED STUDY; CURETTAGE; DIFFERENTIAL DIAGNOSIS; ENDOMETRIUM CARCINOMA; FEMALE; FOAM CELL; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; METAPLASIA; MITOSIS; MUCINOUS CARCINOMA; PRIORITY JOURNAL; UTERINE CERVIX DISEASE; UTERINE CERVIX MICROGLANDULAR HYPERPLASIA;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CELL NUCLEOLUS; CELL NUCLEUS; CERVIX UTERI; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; VACUOLES; VIMENTIN;

EID: 0037869139     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PGP.0000071043.12278.8D     Document Type: Article

References (22)

1. Jones MW, Silverberg SG. Cervical adenocarcinoma in young women: possible relationship to microglandular hyperplasia and use of oral contraceptives. Obstet Gynecol 1989;73:984-9.
2. Candy J, Abell MR. Progestogen-induced adenomatous hyperplasia in women taking oral contraceptives. JAMA 1967;202:637-9.
3. Greeley C, Schroeder S, Silverberg SG. Microglandular hyperplasia of the cervix: a true "pill" lesion? Int J Gynecol Pathol 1995;14:50-4.
4. Young RH, Scully RE. Atypical forms of microglandular hyperplasia of the cervix simulating carcinoma. A report of five cases and review of the literature. Am J Surg Pathol 1989;13:50-6.
5. Zaloudek C, Hayashi GM, Ryan IP, et al. Microglandular adenocarcinoma of the endometrium: a form of mucinous adenocarcinoma that may be confused with microglandular hyperplasia of the cervix. Int J Gynecol Pathol 1997;16:52-9.
6. McCluggage WG, Perenyei M. Microglandular adenocarcinoma of the endometrium. Histopathology 2000;37:285-7.
7. Nucci MR, Prasad CJ, Crum CP, et al. Mucinous endometrial epithelial proliferations: a morphologic spectrum of changes with diverse clinical significance. Mod Pathol 1999;12:1137-42.
8. Fukunaga M. Mucinous endometrial adenocarcinoma simulating microglandular hyperplasia of the cervix. Pathol Int 2000;50:541-5.
9. Dabbs DJ, Geisinger KR, Norris HT. Intermediate filaments in endometrial and endocervical carcinomas. The diagnostic utility of vimentin patterns. Am J Surg Pathol 1986;10:568-76.
10. Coppola D, Fu L, Nicosia SV, et al. Prognostic significance of p53, bcl-2, vimentin, and S100 protein-positive Langerhans cells in endometrial carcinoma. Hum Pathol 1998;29:455-62.
11. McCluggage WG, Sumathi VP, McBride HA, et al. A pattern of Immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aid in the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 2002;21:11-5.
12. Castrillon DH, Kenneth RL, Nucci MR. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol 2002;21:4-10.
13. Marques T, Andrade LA, Vassallo J. Endocervical tubal metaplasia and adenocarcinoma in situ: role of immunohistochemistry for carcinoembryonic antigen and vimentin in differential diagnosis. Histopathology 1996;28:549-50.
14. Shidham VB, Dayer AM, Basir Z, et al. Cervical cytology and immunohistochemical features in endometrial adenocarcinoma simulating microglandular hyperplasia. A case report. Acta Cytol 2000;44:661-6.
15. Wahlstrom T, Lindgren J, Korhonen M, et al. Distinction between endocervical and endometrial adenocarcinoma with immunoperoxidase staining of carcinoembryonic antigen in routine histological tissue specimens. Lancet 1979;2:1159-60.
16. Kamoi S, AIJuboury MI, Akin MR, et al. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint. Int J Gynecol Pathol 2002;21:217-23.
17. Cohen C, Shulman G, Budgeon LR. Endocervical and endometrial adenocarcinoma: an immunoperoxidase and histochemical study. Am J Surg Pathol 1982;6:151-7.
18. Cina SJ, Richardson MS, Austin RM, et al. Immunohistochemical staining for Ki-67 antigen, carcinoembryonic antigen, and p53 in the differential diagnosis of glandular lesions of the cervix. Mod Pathol 1997;10:176-80.
19. Kallakury BV, Ambros RA, Hayner-Buchan AM, et al. Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes. Int J Gynecol Pathol 1998;17:320-6.
20. Ciocca DR, Puy LA, Fasoli LC. Study of estrogen receptor, progesterone receptor, and the estrogen-regulated Mr 24,000 protein in patients with carcinomas of the endometrium and cervix. Cancer Res 1989;1:4298-304.
21. Kohlberger P, Gitsch G, Loesch A, et al. p53 protein overexpression in early stage endometrial cancer. Gynecol Oncol 1996;62:213-7.
22. McCluggage G, McBride H, Maxwell P, et al. Immunohistochemical detection of p53 and bcl-2 proteins in neoplastic and nonneoplastic endocervical glandular lesions. Int J Gynecol Pathol 1997;16:22-7.